Worsening Heart Failure

Heart
#Clinical trials #Corteria Pharmaceuticals #Heart failure #Hormone therapy #Worsening Heart Failure

Phase I study to evaluate treatment of worsening heart failure 

Corteria Pharmaceuticals has initiated a Phase I study to evaluate the company’s first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonist, COR-1167, for the treatment of Worsening Heart Failure (WHF).  COR-1167 is a once-daily subcutaneous CRF2 agonist that has demonstrated substantial protective effects and functional improvement in the heart,… Read More

#News